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ABSTRACT
MicroRNAs (miRNAs) are a class of noncoding RNAs
that regulates target gene expression at posttranscrip-
tional level, leading to further biological functions. We
have demonstrated that microvesicles (MVs) can deliver
miRNAs into target cells as a novel way of intercellular
communication. It is reported that in central nervous
system, glial cells release MVs, which modulate neu-
ronal function in normal condition. To elucidate the
potential role of glial MVs in disease, we evaluated the
effects of secreted astrocytic MVs on stress condition.
Our results demonstrated that after Lipopolysaccharide
(LPS) stimulation, astrocytes released shedding vesi-
cles (SVs) that enhanced vulnerability of dopaminergic
neurons to neurotoxin. Further investigation showed
that increased astrocytic miR-34a in SVs was involved in
this progress via targeting anti-apoptotic protein Bcl-2 in
dopaminergic neurons. We also found that inhibition of
astrocytic miR-34a after LPS stimulation can postpone
dopaminergic neuron loss under neurotoxin stress.
These data revealed a novel mechanism underlying
astrocyte-neuron interaction in disease.
KEYWORDS astrocyte, shedding vesicles, miR-34a,
dopaminergic neurons, Bcl-2
INTRODUCTION
Parkinson’s disease (PD) is characterized by the progressive
degeneration of dopamine (DA) neurons in the substantia
nigra (SN). Circumstantial evidence has shown that the neu-
ron-glia interaction plays an important role inPDpathogenesis
(Furman andNorris, 2014; Lee et al., 2013;Oeckl et al., 2012).
It has been suggested that reactive astrocytesmayamplify the
devastating effects of PD by accelerating the dopaminergic
(DA) neuron loss (Saijo et al., 2009).
Microvesicles (MVs) were originally described as cellular
debris with limited biological function (Morel et al., 2004).
However, increasing amounts of evidence suggest that MV
shedding is a constitutive mode of intercellular communication
(Al-Nedawi et al., 2009; Gupta and Pulliam, 2014; Hu et al.,
2012; Keller et al., 2006; Shantsila et al., 2010). MVs can be
divided into two groups—shedding vesicles (SVs) and exo-
somes—with different discharging processes (Bianco et al.,
2009). The release of shedding vesicles is a result of direct
budding from the plasma membrane, while exosomes are
produced by exocytosis of multivesicular bodies (Zomer et al.,
2010). Bianco F et al. showed that in the central nervous sys-
tem, glial cells can release both type of MVs (Bianco et al.,
2009). Further investigation produced evidence that MVs
released from microglia stimulate synaptic activity via
enhanced sphingolipid metabolism, indicating that microglia
MVs may have signiﬁcant biological functions under normal
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conditions (Antonucci et al., 2012). Our previous work showed
that exosomes can deliver microRNAs (miRNAs) into
endothelial cells and then modulate the migration of the cell by
repressing the target protein expression (Zhanget al., 2010). In
recent years, accumulating evidence also showed that secre-
ted miRNAs in MVs have signiﬁcant biological functions
including effects on cell proliferation, development, differenti-
ation as well as cell death and cancer progression (Hu et al.,
2012; Janowska-Wieczorek et al., 2005; Jung and Suh, 2014;
Liu et al., 2013; Vlassov et al., 2012; Zhou et al., 2014; Zhu and
Fan, 2011). However, there are few studies regarding the
function of secreted miRNAs in neuron-glia interaction of the
central nervous system either in physiological or disease con-
ditions. Whether secreted miRNAs in astrocytic MVs are
involved in PD pathogenesis is still unknown; therefore it is
important to investigate the potential role of MVs in astrocyte-
neuron interactions in PD.
In the present study, we used both in vitro and in vivo PD
models to evaluate the effects of secreted astrocytic MVs under
different conditions on DA neurons survival. We demonstrated
that astrocytes under conditions of LPS stress released SVs,
which enhanced the vulnerability of DA neurons to neurotoxin.
We also found evidence that miR-34a was increased in astro-
cytic SVs after LPS stimulation and that miR-34a then entered
DA cells and repressed the anti-apoptotic protein Bcl-2 (Hock-
enbery et al., 1993; Wang et al., 2009; Yang et al., 1997; Zhou
et al., 2014), thus compromising cellular resistance to neuro-
toxins. In addition, we showed that blocking the astrocytic miR-
34a can rescue the anti-apoptotic function of DA neurons in vitro
and alleviate DA neuron loss as well as abnormal behavior
induced by apomorphine under 6-OHDA stress in vivo. These
data suggest a new mechanism by which astrocytes inﬂuence
neuronal survival under disease conditions.
RESULTS
Biochemical and morphological characterization
of distinct types of microvesicles released
from astrocytic cells
We collected the shedding vesicles (SVs) and exosomes
from the culture medium by differential ultracentrifugation.
EM imaging showed the different sizes of the distinct types of
microvesicles. SVs consisted of cup-shaped vesicles in the
range of 100–200 nm, while exosomes contained relatively
small vesicles of approximately 30–80 nm (Fig. 1A and 1B).
Wealsoanalyzed the different types of vesicles byWestern
blotting of some SVs and exosome markers. Typical SV
markers, such as β1 integrin and ribophorin, were enriched in
our 10,000 ×g pellet, while exosome markers, such as CD63
and heat shock protein HSP70, were found mainly in the
110,000 ×g pellet. Furthermore, we also found Ago2 protein
expression in both types of the releasing microvesicles
(Fig. 1C). Ago2 is reported to be associated with functional
miRNAs, indicating that the released microvesicles might
have carried miRNAs with Ago2 proteins.
Astrocyte-derived shedding vesicles under stress
conditions enhanced the vulnerability of DA neurons
to neurotoxins
Next, we investigated the impact of astrocyte-derived
microvesicles under stress conditions on cell survival. We
found that neither SVs nor exosomes derived from the LPS-
stimulated U87-MG astroglial cell line had any effects on SH-
SY5Y cell viability under normal conditions (Fig. S1). How-
ever, further investigation showed that pretreatment of SVs
derived from LPS-stimulated U87-MG cells increased the
vulnerability of the SH-SY5Y cells to threshold concentra-
tions of neurotoxins, such as 0.2 mmol/L MPP+ or 10 μmol/L
6-OHDA (Figs. 2A, 2B and S1).
MiRNA proﬁling of SVs derived from LPS-stimulated
U-87 MG cells
We collected the SVs from LPS (LPS SVs) and PBS (control
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Figure 1. Morphology and characterization of puriﬁed
microvesicles of U-87 MG cells. (A) EM imaging of
puriﬁed shedding vesicles secreted by U-87 MG cells
(arrows, scale bar = 100 nm); (B) EM imaging of puriﬁed
exosomes secreted by U-87 MG cells (arrows, scale bar =
100 nm); (C) Western blot of the molecular markers of
shedding vesicles (Ribophorin and β1 integrin) and exo-
somes (CD63 and HSP70); both types of microvesicles
contained the miRNA-associated protein Ago2.
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we ﬁrst analyzed the miRNA levels in LPS SVand control SV
using miRNA array. We focused on those miRNAs with a
fold-change (LPS SV/control SV) >2 or <0.5, respectively. In
each group, 10 miRNAs were listed by their signal intensity
in a descending manner (Table S1). Among these altered
miRNAs proﬁles, miR-34a was of particular interest, as it
was upregulated 2.86-fold in LPS SV, and more so, as one of
its predicted genes, Bcl-2, has been demonstrated to regu-
late cell apoptosis (Hockenbery et al., 1993; Yang et al.,
1997). We further assessed the expression level of miR-34a
in LPS SV by qPCR. Consistent with the result of miRNA
array, we found that miR-34a was signiﬁcantly increased,
with a fold change of 3.4 ± 0.7 (Fig. 2C). Because it has been
reported that miR-34a targets Bcl-2 protein, which regulates
cell apoptosis, we proposed that up-regulation of miR-34a in
LPS SVs may contribute to the increased vulnerability of SH-
SY5Y cells to neurotoxins via repressing Bcl-2 expression.
Secreted miR-34a in LPS SVs enhanced
the vulnerability of SH-SY5Y cells to neurotoxins
by repressing Bcl-2 protein expression
We co-cultured the ﬂuorescence-labeled SVs of U-87 MG
cells with SH-SY5Y cells and found labeled SVs in cultured
SH-SY5Y cells by ﬂuorescence microscopy (Fig. 2D). FACS
analysis also showed that the 82.48% of cultured SH-SY5Y
cells were positive for ﬂuorescence-labeled SVs (Fig. 2E).
These results indicated the possibility that SVs may be able
to deliver miRNAs into target cells by co-culture.
As it has been reported that miR-34a may target Bcl-2
protein, we ﬁrst performed the luciferase assay and Western
blot in SH-SY5Y cells which showed that miR-34a can
indeed target Bcl-2 mRNA directly and repress Bcl-2 protein
levels in SH-SY5Y cells (Fig. S2). Next, we further investi-
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Figure 2. SVs derived from LPS-stimulated U-87 MG cells contain increased miR-34a and reduce SH-SY5Y cell viability to
neurotoxins. (A) Cell viability assessed by CCK-8 showed that pretreatment with LPS SVs increased the vulnerability of SH-SY5Y
cells to 0.2 mmol/L MPP+ treatment, *P < 0.05; (B) Cell viability assessed by CCK-8 showed that pretreatment with LPS SVs
increased the vulnerability of SH-SY5Y cells to 10 μmol/L 6-OHDA treatment, *P < 0.05. Control SV: SVs derived from PBS-
stimulated U-87 MG cells; LPS SVs: SVs derived from LPS-stimulated U-87 MG cells; Control Exo: Exosomes derived from control
U-87 MG cells; LPS Exo: Exosomes derived from LPS-stimulated U-87 MG cells; (C) Relative miRNA levels between control SV and
LPS SVs, *P < 0.05; (D) Fluorescent images showed that labeled SVs derived from U-87 MG cells can enter SH-SY5Y cells after co-
incubation; red dots are labeled shedding vesicles, Scale bar = 10 μm; (E) FACS analysis showed that more than 80% of SH-SY5Y
cells carry red ﬂuorescence after co-incubation with labeled SVs; the left histogram represents the control group; the right histogram
represents SH-SY5Y cells co-cultured with the ﬂuorescence-labeled SVs.
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neurotoxin treatment. We found that the level of mature miR-
34a was signiﬁcantly increased in SH-SY5Y cells after the
treatment with LPS SVs (Fig. 3A). As a result, the protein
level of Bcl-2 was repressed in these cells (Fig. 3B and 3C).
However, pretreatment with anti-miR-34a in U-87 MG cells
blocked the increase of miR-34a and negated the repression
of Bcl-2 caused by LPS SVs (Fig. 3A–C). Further investi-
gation showed that cellular viability was reduced and apop-
totic ratio was increased in LPS SV-treated SH-SY5Y cells
after 0.2 mmol/L MPP+ exposure. On the other hand, pre-
treating U-87 MG cells with anti-miR-34a signiﬁcantly less-
ened the effect of LPS SVs on SH-SY5Y cell viability and
apoptotic ratio (Fig. 3D, 3F and 3H). Similar results were
achieved when 6-OHDA was used (Fig. 3E, 3G and 3I).
In addition, we transfected miR-34a into U-87 MG cells
and then collected the SVs (miR-34a SVs) without LPS
stimulation. In these SVs, miR-34a level was increased by
approximately 22.1 ± 2.7 fold (Fig. S3). Pretreatment with
miR-34a SVs increased the levels of mature miR-34a in SH-
SY5Y cells, leading to a decrease in Bcl-2 protein levels
(Fig. 4A–C). Moreover, we also observed that miR-34a SVs
reduced the cellular viability and increased the percentage of
apoptotic SH-SY5Y cells after 0.2 mmol/L MPP+ or 10 μmol/L
6-OHDA treatment (Fig. 4D–I).
Together, these data provide strong evidence that secre-
ted miR-34a in LPS SVs plays a major role in regulating
apoptosis of SH-SY5Y cells exposed to neurotoxins by
repressing Bcl-2 protein expression.
SVs derived from LPS-stimulated astrocytes increased
primary DA neuron loss after neurotoxin exposure
Here, we further used primary culture to verify the results
demonstrated in the cell lines. We collected LPS SVs from
primary astrocytes and found that the miR-34a levels were
also increased (Fig. S4). Pretreatment with primary astro-
cytic LPS SVs caused signiﬁcant TH-positive cell loss after
low concentration MPP+ (0.1 μmol/L) or 6-OHDA (2 μmol/L)
treatment, without signiﬁcant effect on the total neuron
number showed by DAPI (Fig. 5A–D). This effect was
strongly attenuated after blocking the up-regulation of miR-
34a in astrocytic LPS SVs by anti-miR-34a pretreatment in
astrocytes. To further verify that miR-34a is necessary and
sufﬁcient to induce apoptosis, we also used antagomiR
oligonucleotides directed against miR-34a (antagomiR-34a)
to block the level of miR-34a in primary neurons. Similar
results were obtained (Fig. 5A–D). These results indicated
that in an ex vivo situation, stressed astrocytes released SVs
that increased TH neuron vulnerability, in which an increased
level of secreted miR-34a may be involved.
Secreted miR-34a in LPS SVs enhanced the DA neuron
vulnerability to 6-OHDA in vivo
To further understand the role of LPS SVs in vivo, we
evaluated the effects of different groups of SVs in the
6-OHDA rat model. We injected 6-OHDA unilaterally into
the striatum while simultaneously injecting SVs into the SN
in the same side (Fig. 6A). We found that the number of DA
neurons was signiﬁcantly decreased in the LPS SVs-trea-
ted rats after 1 week, while blocking the up-regulation of
miR-34a in LPS SVs can reduce the DA neuron loss at the
same time point. However, when we examined DA neurons
3 weeks after the injection, we found that all groups of rats
showed severe DA neuron loss with no signiﬁcant differ-
ences (Figs. 6B and 2C). We further assessed apomor-
phine-induced contralateral rotation of these rat groups at
different time points (1 week, 2 weeks and 3 weeks
respectively) after the surgery. Among 15 rats for each
group that exhibit abnormal apomorphine-induced rotation
at the third week (>6/min), we found that the probability of
disease onset of the anti-miR-34a + LPS SV group is 3/15
on the ﬁrst week and 5/15 on the second week while the
numbers in scramble + LPS SV group are 8/15 and 11/15
respectively (Fig. 6D). These results showed that blocking
the up-regulation of miR-34a in LPS SVs can signiﬁcantly
delay the disease onset but not able to reverse the disease
progression after the injection.
Taken together, our data suggest that LPS-stimulated
astrocyte SVs can enhance DA neuron vulnerability, which
accelerates the progression of DA neuron loss, and that
miR-34a plays a crucial role in this process.
DISCUSSION
Neuron-glia interaction is thought to play an important role in
the pathogenesis of many neurodegenerative diseases
(Malavolta et al., 2013; Saijo et al., 2009). In the present study,
we revealed a novel mechanism by which astrocytes can
inﬂuence neuronal survival under PD conditions. Our results
Figure 3. Co-incubation with LPS SVs increases miR-34a
level while down-regulates Bcl-2 level that further compro-
mises neurotoxin resistance of SH-SY5Y cells. (A) QPCR
analysis of miR-34a levels in SH-SY5Y cells after co-incubation
withdifferent groupsofSVs, **P<0.01; (BandC)Western-blotand
quantiﬁcation of Bcl-2 protein levels in SH-SY5Y cells after co-
incubation with different groups of SVs, *P < 0.05; (D and E)
Viability of SH-SY5Y cells pre-treated with different groups of SVs
following 0.2 mmol/L MPP+ or 10 μmol/L 6-OHDA stress,
*P < 0.05; (F andG) TUNEL staining of SH-SY5Y cells pre-treated
with different groups of SVs after 0.2 mmol/L MPP+ or 10 μmol/L
6-OHDA stress, scale bar = 50 μm; (H and I) Percentage of
TUNEL positive cells among SH-SY5Y cells pre-treated with
different types of SVs after 0.2 mmol/L MPP+ or 10 μmol/L
6-OHDA stress, *P < 0.05, **P < 0.01; Control SV: SVs derived
from control U-87 MG cells; LPS SV: SVs derived from LPS-
stimulated U-87 MG cells; anti miR-34a + LPS SV: SVs derived
from LPS-stimulated U-87 MG cells transfected with miR-34a
inhibitor; Scramble + LPS SV: SVs derived from LPS-stimulated
U-87 MG cells transfected with scramble RNA.
s
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demonstrated that reactive astrocytes release SVs (not exo-
somes), which increase the percentage of apoptotic SH-SY5Y
cells after treatment with low concentrations of neurotoxins.
Thus, these SVs may increase DA neuron vulnerability. Fur-
thermore, we demonstrated that there are differences in
miRNA expression patterns between SVs produced by reac-
tive and resting astrocytes and that miR-34a was signiﬁcantly
up-regulated. Our previous work demonstrated that MVs can
deliver miRNAs into target cells and shut down target gene
expression (Zhang et al., 2010). In addition, several studies
revealed that MVs mediated cell interaction exists in central
nervous system (Antonucci et al., 2012; Hu et al., 2012).
Moreover, there is evidence that miR-34a targets the anti-
apoptotic protein, Bcl-2, which can further induce tubular cell
apoptosis (Liu et al., 2011; Sun et al., 2012;Wang et al., 2009;
Zhou et al., 2014). Here we also performed luciferase assay
which ensure that miR-34a can directly bind and regulate Bcl-
2 in SH-SY5Y cells. These data together indicate the possi-
bility that astrocytic miR-34a may be transferred into neurons
via SVs, where it then represses Bcl-2 protein levels and
decreases the anti-apoptotic function of the targeted neurons.
Notably, several other miRNAs listed in Table S1 also have
important functions in modulating cell apoptosis. Among up-
regulated miRNAs, miR-18a was validated to regulate cell
apoptosis by targeting Bcl-2 directly in mice and humans
(Scherr et al., 2014), and miR-296-3p was found to increase
apoptosis levels of an islet cell line αTC1-6 cells (Barbagallo
et al., 2013). On the other hand, in those down-regulated
miRNAs, inhibition of miR-708 promoted the apoptosis of
SW480 cells (Lei et al., 2014) andT24cells (Songet al., 2013).
These data suggest that in addition to miR-34a, those altered
miRNAs summarized in Table S1 may also affect cell apop-
tosis. Nevertheless, our data demonstrated that the level and
variation of miR-34a in astrocytic SVs is one of the highest
among these miRNAs upon LPS stimulation, which indicates
that miR-34a plays a major role in modulating cell apoptosis.
Furthermore, we provided direct evidence that ﬂuores-
cence-marked astrocytic SVs can enter target cells after 24 h
of incubation, increase miR-34a levels and decrease Bcl-2
protein levels in SH-SY5Y cells. Blocking the increase in the
miR-34a levels in astrocytic SVs by a miR-34a inhibitor
alleviated the DA cell loss caused by LPS-stressed astro-
cytic SVs. This evidence indicates that increased miR-34a
levels may contribute to the disruptive effect of reactive-as-
trocytic SVs on DA cell survival. Since our miRNAs array
data indicated that the level of several other miRNAs also
changed in astrocytic SVs after LPS stimulation, we further
testify the effect of miR-34a by over-expression experiment.
When we increased the miR-34a levels in astrocytic SVs
without LPS stimulation by transfecting astrocytes with pre-
miR-34a, we found that those SVs still enhanced the vul-
nerability of DA neurons to low concentrations of neurotox-
ins, leading to an increased percentage of apoptotic cells.
These results strongly indicated that the upregulation of miR-
34a in astrocytic SVs is sufﬁcient to increase neuronal vul-
nerability under disease conditions.
In primary culture, we found that LPS-stimulated rat
astrocytes also generated SVs with higher levels of miR-34a.
In addition, SVs derived from LPS-stressed primary astro-
cytes enhanced primary DA neuron vulnerability to low
concentrations of both MPP+ and 6-OHDA. This disruptive
effect was alleviated when we blocked the increase of miR-
34a using a miR-34a inhibitor. All of these results were
consistent with the data obtained from the cell lines, which
suggests that a similar mechanism exists for both primary
and cell line culture systems.
Next, we investigated the role of secreted miR-34a in
astrocytic SVs in regulating neuron survival in vivo. Using
the 6-OHDA model, we demonstrated that SVs derived from
LPS-stimulated primary astrocytes signiﬁcantly accelerated
DA neuron loss following 6-OHDA treatment. Most of the rats
lost more than 30% of their DA neurons in the ﬁrst week and
showed apomorphine-induced rotation. When we blocked
the increase of miR-34a in astrocytic SVs by transfecting
miR-34a inhibitor into primary astrocytes, we found that the
acceleration of DA neuron loss was reduced and that apo-
morphine-induced rotation was delayed compared with
scramble group. These data indicate that the increased
levels of secreted miR-34a in LPS-stimulated-astrocytic SVs
play a crucial role in the acceleration of DA neuron loss.
Recently, it is reported that miR-34a is shuttled in exosomes
which induces cell apoptosis in ﬁbrotic kidney (Zhou et al.,
2014). This is similar with our ﬁndings in nervous system
except that in our model we demonstrated that SVs contain
the increase of miR-34a and display robust effect rather than
exosomes in regulating cell apoptosis. When we examined
those PD rats three weeks after 6-OHDA injection, we found
all groups showed severe DA neuron loss. Combined with
behavioral tests, it is indicated that blocking the function of
secreted miR-34a in LPS-stimulated astrocytic SVs can
postpone but not reverse the progress of disease.
Figure 4. Overexpression of miR-34a in SVs is sufﬁ-
cient to increase the vulnerability of SH-SY5Y cells to
neurotoxins. (A) QPCR analysis of miR-34a levels in SH-
SY5Y cells after co-incubation with miR-34a SV compared
with cells co-incubated with control SV, *P < 0.05; (B and
C) Western-blot and quantiﬁcation of Bcl-2 protein levels in
SH-SY5Y cells after co-incubation with miR-34a SV
compared with cells co-incubated with control SV,
*P < 0.05; (D and E) Viability of SH-SY5Y cells pre-treated
with different groups of SVs after 0.2 mmol/L MPP+ or 10
μmol/L 6-OHDA stress, *P < 0.05; (F and H) TUNEL
staining of SH-SY5Y cells pre-treated with different groups
of SVs after 0.2 mmol/L MPP+ or 10 μmol/L 6-OHDA
stress, scale bar = 50 μm; (G and I) Percentage of TUNEL
positive cells of SH-SY5Y cells pre-treated with different
types of SVs after 0.2 mmol/L MPP+ or 10 μmol/L 6-OHDA
stress, *P < 0.05, **P < 0.01. Control SV: SVs derived from
control U-87 MG cells; miR-34a SV: SVs derived from
U-87 MG cells that overexpressed miR-34a.
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in the number of reactive astrocytes has been observed (Forno
etal., 1992),whichsuggest that astrocytesplayvital roles inPD.
In the 6-OHDA animal model of PD, Stromberg found an
increased amount of reactive astrocytes in the striatum
(Stromberg et al., 1986). Activation of astrocytes is a prevalent
response to neuronal damage in neurodegenerative diseases,
with potential neurotoxic and neuroprotective consequences.
Severalﬁndingssuggestaneuroprotective role forastrocytes in
PD as well as animal models of PD. Saura et al. found infusion
of IL-1β led to an increased activation of astrocytes in the the



























































































































































Figure 5. SVs derived from LPS-stimulated primary astrocytes enhance DA neurons loss after treatment with neurotoxins.
(A and C) TH staining and quantiﬁcation of the percentage of TH-positive cells among primary neurons pre-treated with different
groups of SVs after 0.1 μmol/L MPP+ stress, *P < 0.05, **P < 0.01. Inset: DAPI staining of the cell nuclei in the ﬁeld of view. (B and D)
TH staining and quantiﬁcation of the percentage of TH-positive cells among primary neurons pre-treated with different groups of SVs
after 2 μmol/L 6-OHDA stress, *P < 0.05, **P < 0.01, scale bar = 200 μm. Inset: DAPI staining of the cell nuclei in the ﬁeld of view.
Control: a control group of neuron culture without SVs incubation; Control SV: SVs derived from primary astrocytes; LPS SV: SVs
derived from LPS-stimulated primary astrocytes; anti-miR-34a + LPS SV: SVs derived from LPS-stimulated primary astrocytes
transfected with miR-34a inhibitor; Sc antimiR + LPS SV: SVs derived from LPS-stimulated primary astrocytes transfected with
scramble RNA; Sc antagomiR + LPS SV: SVs derived from LPS-stimulated primary astrocytes, and the primary neurons were
pretreated with scramble antagomiR; antagomiR-34a + LPS SV: SVs derived from LPS-stimulated primary astrocytes, and the
primary neurons were pretreated with antagomiR-34a.
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against 6-OHDA (Saura et al., 2003). It also has been shown
that astrocytes can protect neurons from NO toxicity by a glu-
tathione dependent mechanism (Chen et al., 2001). Addition-
ally, astrocytes express monoamine oxidase-B and catechol-
O-methyl-transferaseare, thus reducing the oxidative stress by
metabolizingdopamine (Hirschet al., 1999).On the other hand,
Li et al. found that suitable activation of astrocytes increased
their protection effect on dopaminergic neurons stimulated by
LPS, while excessive activation attenuated it, which suggested
that astrocytes played a double-faced effect on dopaminergic
neurons (Li et al., 2009). Also, astrocytes can release
chemokines and cytokines that are deleterious to neurons in
variousmodels of PD, such as reactive oxygen species, nitrite,
S100B and so on (Niranjan et al., 2010). The present study
suggested that astrocytes had a destructive effect through SV-
miR-34a-Bcl2 pathway under LPS stress condition. These
results suggest that in stress condition, activated astrocytes
may act as a double-edged sword in regulating DA neurons
survival. Such functional balance of reactive astrocytes needs
to be further explored. Altogether, our results suggested that
under stress conditions, such as LPS stimulation, increased
levels of miR-34a in astrocytic SVs can be transported into DA
neurons,where theyenhance the vulnerability of theneurons to
neurotoxins by targeting the anti-apoptotic protein Bcl-2. The
increase of astrocytic miR-34a in disease conditions may be a
potential target for alleviation of PD progress.
MATERIALS AND METHODS
Animals and cell culture
All of the animal care and experimental procedures were performed
in accordance with the Laboratory Animal Care Guidelines approved
by the Model Animal Research Center of Nanjing University. U-87
MG and SH-SY5Y cell lines were maintained in Dulbecco’s Modiﬁed
Eagle Medium: Nutrient Mixture F-12 (DMEM/F-12, Life Technolo-
gies, Grand Island, NY, USA) with 10% Fetal Bovine Serum (FBS,
Life Technologies). Primary cultures of rat brain astrocytes were
prepared as follows: brieﬂy, newborn (P0) rat cerebral cortices were
separated in Hank’s Balanced Salt Solution (HBSS, Life Technolo-
gies) and digested into cell suspensions. Digestion was terminated
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Figure 6. SVs derived from LPS-stimulated primary astrocytes accelerates DA neurons loss as well as disease onset in
6-OHDA rat model. (A) Schematic diagram of the experiment process; (B) TH-immunoreactive cell bodies in SN of different groups of
rats; (C) Quantiﬁcation of DA neurons loss among different groups of rats, *P < 0.05 (n = 10 in each group); (D) The Kaplan-Meier
curves demonstrate the probability of disease onset, *P < 0.05. (n = 15 in each group).
Neuron-glia interaction mediated by secreted miRNA RESEARCH ARTICLE









maintained in DMEM/F-12 medium containing 10% FBS. After 14
days of culture, the astrocytes were separated from the microglia
and oligodendrocytes by shaking for 12 h in an orbital shaker at
240 rpm. Cell samples were checked regularly for the expression of
glial ﬁbrillary acid protein, a marker for astrocytes. Only those cul-
tures containing >95% astrocytes were used. Primary cultures of rat
DA neurons were prepared as follows: brieﬂy, embryonic (E14.5) rat
ventral mesencephalon (VM) was removed from the brains in HBSS
and digested into cell suspensions. Digestion was terminated by the
addition of 10% FBS. Cells were seeded in 24-well plates that were
coated with 0.05% poly-D-lysine (Sigma-Aldrich, St Louis, MO) and
maintained in neurobasal medium (Life Technologies) containing 2%
B27 (Life Technologies) and 0.2 mmol/L L-glutamine (Life Tech-
nologies) for 4 more days in vitro before use. U-87 MG cells and
primary astrocytes were treated with different concentrations of LPS
(Sigma-Aldrich) for 6 h and washed three times with PBS. The
conditioned medium was collected after another 48 h culture.
SH-SY5Y cells and primary DA neurons were treated with different
groups of astrocytic SVs in an astrocyte-to-neuron ratio of 9:1 for
24 h before exposure to neurotoxin. SH-SY5Y cells were exposed to
different concentrations of 1-Methyl-4-phenylpyridinium iodide
(MPP+, Sigma-Aldrich) or 6-Hydroxydopamine hydrobromide
(6-OHDA, Sigma-Aldrich) for 6 h and cultured for another 24 h
before subsequent assays. Primary DA neurons were exposed to
different concentrations of MPP+ or 6-OHDA for 1 h and cultured for
another 24 h before subsequent assays.
MVs isolation and electronic microscopy
MVs were isolated from culture medium by differential centrifugation
as in previous publications (Bianco et al., 2009). After removing cells
and other debris by centrifugation at 300 ×g and 1200 ×g, the
supernatant was centrifuged at 10,000 ×g for 1 h to collect the
shedding vesicles (SVs) and at 110,000 ×g for 2 h to collect the
exosomes; all steps were performed at 4°C. MVs were collected
from the pellet and resuspended in FBS-free medium. In preparation
for Electron Microscope (EM) imaging, MVs were precipitated, ﬁxed
in a 0.1 mol/L phosphate buffer containing 2.5% glutaraldehyde
(Sigma-Aldrich), and cut into 50 µm-thick sections using a vibra-
tome. The sections were postﬁxed with 1% OsO4, dehydrated and
embedded in Durcupan (ACM; Fluka, Buchs, Switzerland) on a
microscope slide and covered with a coverslip. The sections were
cut again using a Reichert ultramicrotome into 70-nm-thick sections.
The ultrathin sections were then stained with uranyl acetate and lead
citrate and evaluated with an electron microscope.
RNA isolation, microRNA array and quantitative real-time PCR
of mature miRNAs
The total RNA of the MVs derived from 108 cells was extracted using
TRIzol Reagent (Life Technologies). Samples of total RNA were
extracted for miRNAs Affymetrix GeneChip miRNA 3.0 array anal-
ysis (Life Technologies). Quantitative real-time PCR (qPCR) was
performed using TaqMan microRNA probes (Applied Biosystems,
Foster City, CA, USA) according to the manufacturer’s instructions.
Brieﬂy, 1 μg of the total RNA was reverse-transcribed to produce
cDNA using Avian Myeloblastosis Virus reverse transcriptase
(Takara, Dalian, China) and stem-loop RT primers (Applied Biosys-
tems). Real-time PCR was performed using a TaqMan PCR kit and
an Applied Biosystems 7300 Sequence Detection System (Applied
Biosystems). All of the reactions, including the no-template controls,
were run in triplicate. After the reactions, the CT values were
determined using ﬁxed-threshold settings.
Fluorescence labeling of SVs
U-87 MG cells were treated with SynaptoGreen (Sigma-Aldrich) for
6 h and washed ﬁve times with PBS; after the cells were cultured for
another 48 h, the medium was collected and the SVs were isolated.
The collected SVs were added into the SH-SY5Y cells in an astro-
cyte-to-neuron ratio of 9:1 for 24 h. Subsequently, the SH-SY5Y cells
were collected and analyzed by ﬂuoromicroscopy or Fluorescence
Activated Cell Sorter (FACS).
Cell transfection with ncRNA, anti-miR-34a or pre-miR-34a
U-87 MG cells, primary astrocytes and primary neurons were
transfected using Lipofectamine 2000 (Life Technologies) according
to the manufacturer’s instructions. For overexpression of miR-34a,
50 nmol/L of pre-miR-34a or scrambled negative control pre-miRNA
(pre-ncRNA) was used. For knockdown of miR-34a, 20 nmol/L of
anti-miR-34a, 50 nmol/L of antagomiR oligonucleotides directed
against miR-34a or scrambled negative control anti-miRNA (anti-
ncRNA) was used. Cell media were collected 48 h after transfection.
Luciferase assay
The 3′UTR of Bcl-2 containing the predicted target sequence was
cloned and inserted into pMIR-REPORTTM-Luciferase vector (Am-
bion, Austin, TX, USA). Forward primer: 5′-CATGCCTGCCCCAAA-
CAAATA-3′; reverse primer: 5′-AGGGCATTTTTCCCATCGCT-3′.
Mutated vector was generated in Invitrogen by replacing the predicted
target region with its reverse sequence (from ACUGCC to TGACGG).
SH-SY5Y cells were seeded in 24 well plates for 12 h. Afterwards, 0.2
μg of ﬁreﬂy luciferase reporter plasmid, 0.2 μg of β-galactosidase (β-
gal) expression vector (Ambion), and 50 nmol/L of miR-34a mimics or
scrambled control were transfected into cells. Cellswere harvested for
luciferase assay (Promega, Madison, WI, USA) 24 h later, and luci-
ferase activities were normalized to β-gal activities.
CCK-8 Assay
Cytotoxicity was also assayed using CCK-8 (Dojindo, Kumamoto,
Japan) assay. Brieﬂy, SH-SY5Y cells were cultured in a 96-well plate
with different treatments. The cells were then treated with 10 μL
CCK-8 solution per well and incubated for 3 h at 37°C. The amount
of formazan dye generated by cellular dehydrogenase activity was
measured by absorbance at 450 nm with a microplate reader.
TUNEL assay
For the TUNEL assay, the cells were harvested and washed with
PBS, ﬁxed and permeabilized, and then TUNEL-labeled using a One
Step TUNEL Apoptosis Assay Kit (Beyotime, China) as instructed.
The total percentage of apoptotic cells was estimated by determining
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the percentage of cells with positive TUNEL staining in ﬁve randomly
selected ﬁelds from each slide under a microscope.
TH staining
After treatment, primary DA cultures were washed with PBS and
ﬁxed with 4% paraformaldehyde (PFA) for 15 min. Then, the cells
were blocked in PBS with 5% horse serum and 0.03% Triton X-100
for 1 h. Immunocytochemistry was performed using mouse anti-ty-
rosine hydroxylase monoclonal antibody (Sigma). The percentage of
cells with positive TH staining was estimated in ﬁve randomly
selected ﬁelds under a ﬂuorescent microscope.
Experimental animals were anesthetized and perfused tran-
scardially with 0.9% saline followed by 4% PFA. Brain samples were
postﬁxed with 4% PFA overnight and equilibrated in 15% and 30%
sucrose. Coronal sections of 40 μm were prepared with a sliding
microtome. Immunohistochemistry was performed using mouse anti-
tyrosine hydroxylase monoclonal antibody. Unbiased quantiﬁcation
of TH-immunoreactive neurons in the SN was performed according
to the optical fractionator principle (Gundersen et al., 1988).
Intracerebral injection
Animals received two 2.5-μL stereotaxic injections of 2.0 μg/μL
6-OHDA (total dose = 10 μg 6-OHDA) delivered at a rate of 0.5 μL/min
and the syringewas left in place for an extra 5min and thenwithdrawn
gently, and the skin was sutured. Striatum injection coordinates were
as follows: site 1: AP+1.3, ML −2.8, DV −4.5; site 2: AP −0.6,ML −4.0,
DV −5.5; and tooth bar set at −3.2. The lesionwas allowed to progress
for 1–3 weeks after that animals were killed for further analyses.
The vesicles (1 μg/μL, protein concentration) were injected at two
sites (site 1: AP −4.8, ML −2.0, DV −7.1; site 2: AP −5.5, ML −1.9,
DV −7.0) stereotaxically over the SN (2.5 μL /site). Injection rate was
0.5 μL/min and the needle was left in place for 10 min before it was
slowly retracted from the brain.
Behavioral analysis
The animals were tested for apomorphine-induced (0.2 mg/kg, i.p.)
turning 1, 2 and 3 weeks after intracerebral injection. Only the rats
that exhibited a mean rotation toward the healthy side at least 6.0 full
body turns per min were considered as disease onset.
Statistical analysis
All experiments were performed in triplicate. Data were presented as
the mean ± SEM; statistical signiﬁcance of difference (P value) was
assessed using Student’s t-test by GraphPad Prism 5 software
(GraphPad, San Diego, CA, USA), and P < 0.05 was considered
signiﬁcant.
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